ESTRO 2024 - Abstract Book

S1061

Clinical - Gynaecology

ESTRO 2024

2055

Digital Poster

SBRT in recurrent oligometastatic ovarian cancer : An EORTC Y-ECI GCG systematic review.

Melpomeni Kountouri 1 , Constance Huck 2 , Gloria Marquina 3,4 , Manuel Espantaleon 5 , Ainhoa Madariaga 6 , Judith Kroep 7 , Fernanda Herrera 2,8 , Noelia Sanmamed 9 1 Hôpitaux Universitaires de Genève, Radiation Oncology Department, Genève, Switzerland. 2 Centre Hospitalier Universitaire Vaudois, Radiation Oncology Department, Lausanne, Switzerland. 3 Hospital Clínico San Carlos, IdISSC, Medical Oncology Department, Madrid, Spain. 4 Complutense University (UCM), School of Medicine, Madrid, Spain. 5 Hospital Clínico San Carlos, Clinico San Carlos University Hospital Library, Madrid, Spain. 6 12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain. 7 Leiden University Medical Center, Medical Oncology Department, Leiden, Netherlands. 8 Centre Hospitalier Universitaire Vaudois, Immuno-Oncology Department, Lausanne, Switzerland. 9 Clínico San Carlos University Hospital, Radiation Oncology Department, Madrid, Spain Recurrent oligometastatic ovarian cancer with limited disease burden has been challenging to manage. Targeted effective treatment while ensuring limited toxicity is essential, to allow a break from systemic therapies and simultaneously increasing local disease control. Radiotherapy has played an emerging role in ovarian cancer to palliate symptoms and/or to prolong chemotherapy-free intervals. The development of stereotactic body radiotherapy (SBRT) allows ablative doses to be delivered while reducing the dose to the adjacent organs at risk. Nevertheless, there is currently limited evidence on the role of SBRT in metachronous ovarian oligometastatic disease. The primary objective of this systematic review is to assess the progression free survival (PFS) following SBRT in oligometastatic recurrent ovarian cancer. Secondarily, acute and late toxicity as well as overall response rate (ORR), time to the next systemic therapy and overall survival (OS) were evaluated. Purpose/Objective:

Material/Methods:

A comprehensive search according to the Preferred Reporting Items for Systematic Reviews and Meta analyses (PRISMA) recommendations was undertaken and the study was registered in PROSPERO (ID CRD42023412324). Inclusion criteria required all published journal articles in English reporting PFS outcomes following SBRT in recurrent oligometastatic visceral or nodal ovarian disease, independent of platinum sensitivity, while exclusion criteria omitted publications reporting outcomes following central nervous system treatment. A subgroup analysis was performed evaluating the site of metastases, radiotherapy treatment and acute and late toxicity where reported.

Results:

Following the screening of 834 studies, 9 publications were included in the final analysis, consisting of 3 case reports, 5 retrospective studies and one phase I study. In the overall population, 426 patients with a median age of 61.2 years (range 28 - 85 years) were treated. The median number of systemic treatments previous to irradiation